Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study.

Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC.

Gastroenterology. 2014 Jul;147(1):143-151.e5. doi: 10.1053/j.gastro.2014.03.048. Epub 2014 Apr 1.

PMID:
24704525
2.

Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.

Wang JP, Kao FY, Wu CY, Hung YP, Chao Y, Chou YJ, Li CP.

Cancer. 2015 May 1;121(9):1446-55. doi: 10.1002/cncr.29159. Epub 2014 Dec 23.

3.

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A.

J Hepatol. 2010 Aug;53(2):348-56. doi: 10.1016/j.jhep.2010.02.035. Epub 2010 Apr 27. Review.

4.

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.

Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study Group.

Gut. 2011 Aug;60(8):1109-16. doi: 10.1136/gut.2010.221846. Epub 2011 Jan 26.

PMID:
21270118
5.

Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.

Hsu YC, Wu CY, Lane HY, Chang CY, Tai CM, Tseng CH, Lo GH, Perng DS, Lin JT, Mo LR.

J Antimicrob Chemother. 2014 Jul;69(7):1920-7. doi: 10.1093/jac/dku041. Epub 2014 Feb 26.

6.
7.

The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.

Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP.

Aliment Pharmacol Ther. 2014 Dec;40(11-12):1262-9. doi: 10.1111/apt.12990. Epub 2014 Oct 13.

8.

Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B.

Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT.

J Infect Dis. 2016 Mar 15;213(6):966-74. doi: 10.1093/infdis/jiv547. Epub 2015 Nov 17.

PMID:
26582959
9.

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.

Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

Hepatology. 2013 Jul;58(1):98-107. doi: 10.1002/hep.26180. Epub 2013 Mar 6.

PMID:
23213040
10.

Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.

Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M; CHeCS Investigators.

Clin Gastroenterol Hepatol. 2014 May;12(5):885-93. doi: 10.1016/j.cgh.2013.09.062. Epub 2013 Oct 6.

PMID:
24107395
11.

Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.

Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.

J Gastroenterol Hepatol. 2012 Oct;27(10):1589-95. doi: 10.1111/j.1440-1746.2012.07167.x.

PMID:
22554121
12.

Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine.

Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ.

Gastroenterology. 2014 Jul;147(1):152-61. doi: 10.1053/j.gastro.2014.02.033. Epub 2014 Feb 25.

PMID:
24583062
13.

Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.

Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A.

J Viral Hepat. 2013 Jul;20(7):502-9. doi: 10.1111/jvh.12054. Epub 2013 Feb 6.

PMID:
23730844
14.

Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study.

Yeh YC, Liu CJ, Kuo RN, Lai CL, Shau WY, Chen PJ, Lai MS.

PLoS One. 2014 Jul 15;9(7):e102051. doi: 10.1371/journal.pone.0102051. eCollection 2014.

15.

Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma.

Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ; REVEAL–HBV Study Group.

Clin Gastroenterol Hepatol. 2013 Dec;11(12):1636-45.e1-3. doi: 10.1016/j.cgh.2013.04.043. Epub 2013 May 10.

16.

Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis.

Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J.

J Hepatol. 2013 Mar;58(3):427-33. doi: 10.1016/j.jhep.2012.10.025. Epub 2012 Oct 30.

PMID:
23123221
17.

Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.

Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Wong VW.

Gastroenterology. 2013 May;144(5):933-44. doi: 10.1053/j.gastro.2013.02.002. Epub 2013 Feb 12.

PMID:
23415803
18.

Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: a retrospective cohort study.

Seo SI, Choi HS, Choi BY, Kim HS, Kim HY, Jang MK.

J Med Virol. 2014 Jan;86(1):124-30. doi: 10.1002/jmv.23779. Epub 2013 Oct 11.

PMID:
24127328
19.

Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study.

Fu SC, Huang YW, Wang TC, Hu JT, Chen DS, Yang SS.

Aliment Pharmacol Ther. 2015 Jun;41(11):1200-9. doi: 10.1111/apt.13191. Epub 2015 Apr 6.

PMID:
25846548
20.

Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.

Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY.

Hepatology. 2013 Jul;58(1):150-7. doi: 10.1002/hep.26300. Epub 2013 May 15.

PMID:
23389758
Items per page

Supplemental Content

Write to the Help Desk